SCHEMBL5454730

SCHEMBL5454730

Cc1ccc2[nH]c3c(c2c1)CCCC3NC(=O)Nc1ccc(Cl)cc1Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.61
ALOX15 P16050 3/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
MAPK1 P28482 1/20 0.61
DHODH Q02127 1/20 0.54
GAA P10253 1/20 0.53
CASP6 P55212 1/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
GLA P06280 1/20 0.53
SIRT1 Q96EB6 9/20 0.52
SIRT2 Q8IXJ6 4/20 0.51
RECQL P46063 1/20 0.51
BRD3 Q15059 1/20 0.51
LMNA P02545 2/20 0.48
SIRT3 Q9NTG7 2/20 0.48
RAB9A P51151 1/20 0.48
PRMT5 O14744 1/20 0.48
TP53 P04637 1/20 0.47
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459031 0.87 SMN1; SMN2 (0.63) MAPTALOX15SMN1; SMN2MAPK1DHODH
SCHEMBL4030994 0.81 SIRT1 (0.59) MAPTALOX15SMN1; SMN2MAPK1DHODH
SCHEMBL5454043 0.80 BRD3 (0.57) MAPTALOX15SMN1; SMN2MAPK1DHODH
SCHEMBL5452761 0.80 GAA (0.56) MAPTALOX15SMN1; SMN2MAPK1DHODH
SCHEMBL4161447 0.79 BRD3 (0.77) MAPTALOX15SMN1; SMN2MAPK1DHODH
SCHEMBL4030859 0.79 ALOX15 (0.70) MAPTALOX15SMN1; SMN2MAPK1DHODH
SCHEMBL5456594 0.79 GAA (0.62) MAPTALOX15SMN1; SMN2MAPK1DHODH
SCHEMBL16946171 0.78 MAPT (0.75) MAPTALOX15SMN1; SMN2MAPK1DHODH
SCHEMBL15577169 0.78 MAPT (0.75) MAPTALOX15SMN1; SMN2MAPK1DHODH
SCHEMBL5445807 0.78 GAA (0.61) MAPTALOX15SMN1; SMN2MAPK1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276009-A1 Compositions and Methods for Viral Inhibition MAVS, SARS1, ZC3HAV1 MAPT 3817/4885ALOX15 655/4885SMN1; SMN2 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.